دورية أكاديمية
أعرض في EDS

Rapid Identification of Rectal Multidrug-resistant Escherichia coli Before Transrectal Prostate Biopsy.

التفاصيل البيبلوغرافية
العنوان: Rapid Identification of Rectal Multidrug-resistant Escherichia coli Before Transrectal Prostate Biopsy.
المؤلفون: Tchesnokova VL; Department of Medicine, VA Healthcare System Minneapolis, Minneapolis, MN., Ottley LL; Departments of Medicine and Urology, VA Healthcare System San Diego, San Diego, CA., Sakamoto K; Departments of Medicine and Urology, VA Healthcare System San Diego, San Diego, CA; Department of Urology, University of California, San Diego School of Medicine, La Jolla, CA., Fierer J; Departments of Medicine and Urology, VA Healthcare System San Diego, San Diego, CA; Department of Medicine, University of California, San Diego School of Medicine, La Jolla, CA; Department of Pathology, University of California, San Diego School of Medicine, La Jolla, CA., Sokurenko E; Department of Urology, University of California, San Diego School of Medicine, La Jolla, CA; Department of Microbiology, University of Washington, Seattle, WA., Liss MA; Department of Urology, University of Texas Health Science Center San Antonio, San Antonio, TX. Electronic address: mliss008@gmail.com.
المصدر: Urology [Urology] 2015 Dec; Vol. 86 (6), pp. 1200-5. Date of Electronic Publication: 2015 Aug 20.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Country of Publication: United States NLM ID: 0366151 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-9995 (Electronic) Linking ISSN: 00904295 NLM ISO Abbreviation: Urology Subsets: MEDLINE
أسماء مطبوعة: Publication: New York : Elsevier Science
Original Publication: Ridgewood, N.J., Professional Medical Services Co.
مواضيع طبية MeSH: Drug Resistance, Multiple, Bacterial* , Preoperative Care*, Escherichia coli/*isolation & purification , Prostate/*pathology , Rectum/*microbiology, Aged ; Anti-Bacterial Agents/pharmacology ; Area Under Curve ; Biopsy, Needle ; Escherichia coli/drug effects ; Escherichia coli/genetics ; Fluoroquinolones/pharmacology ; Humans ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Multiplex Polymerase Chain Reaction/methods ; ROC Curve ; Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology
مستخلص: Objective: To develop and evaluate a rapid multiplex-quantitative polymerase chain reaction (qPCR) to identify fecal carriers of multidrug-resistant extraintestinal pathogenic Escherichia coli (MDR-ExPEC) clonal groups.
Methods: Men presenting for transrectal prostate biopsy (TPB) at the San Diego Veterans Affairs Medical Center underwent rectal culture immediately before TPB. Rectal swabs were streaked onto ciprofloxacin-supplemented (4 mg/L) MacConkey agar plates, identified, and susceptibility tested. The same swab was sent to the University of Washington for qPCR test (EST200) targeting 2 major MDR-ExPEC clonal groups--ST131 and ST69--that combined were expected to represent majority of fluoroquinolone (FQ)- and trimethoprim-sulfamethoxazole-resistant E coli. We calculate test characteristics including the area under the receiver operative curve (AUC).
Results: We enrolled 104 men from 11/5/2013 to 6/10/2014. FQ-resistant E coli were cultured from 19.2% (20/104) of rectal swabs, and 26% (27/104) of all swabs were positive for EST200 by PCR. The test characteristics comparing the EST200 to the culture-based detection of FQ resistance were 75%, 86%, 94%, and 56%, respectively. The AUC was 0.84 for the EST200 to detect FQ resistance before TPB.
Conclusion: Compared to the reference standard rectal culture, EST200 was able to detect majority of FQ-resistant E coli on rectal swabs before prostate biopsy.
(Copyright © 2015 Elsevier Inc. All rights reserved.)
References: BJU Int. 2009 Dec;104(11):1556-8. (PMID: 20053186)
Urology. 2009 Dec;74(6):1200-5. (PMID: 19815258)
J Urol. 2000 Jul;164(1):76-80. (PMID: 10840428)
J Urol. 2001 Sep;166(3):856-60. (PMID: 11490233)
Urology. 2002 Nov;60(5):826-30. (PMID: 12429309)
J Urol. 2003 May;169(5):1762-5. (PMID: 12686828)
Yonsei Med J. 2004 Aug 31;45(4):598-608. (PMID: 15344199)
J Urol. 1997 Jun;157(6):2199-200. (PMID: 9146614)
Urology. 1998 Oct;52(4):552-8. (PMID: 9763070)
J Infect Chemother. 2008 Feb;14(1):40-3. (PMID: 18297448)
J Urol. 2008 Mar;179(3):952-5; discussion 955. (PMID: 18207185)
Urology. 2009 Aug;74(2):332-8. (PMID: 19464041)
J Urol. 2010 Mar;183(3):963-8. (PMID: 20089283)
BJU Int. 2010 Oct;106(7):1017-20. (PMID: 20346055)
J Urol. 2011 Apr;185(4):1283-8. (PMID: 21334021)
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. (PMID: 21685461)
Can J Urol. 2012 Dec;19(6):6573-7. (PMID: 23228295)
J Infect Dis. 2013 Mar 15;207(6):919-28. (PMID: 23288927)
Urology. 2013 Mar;81(3):548-55. (PMID: 23333000)
BJU Int. 2013 May;111(6):946-53. (PMID: 23464844)
J Clin Microbiol. 2013 Sep;51(9):2991-9. (PMID: 23843485)
J Antimicrob Chemother. 2014 Mar;69(3):809-14. (PMID: 24123431)
Int J Antimicrob Agents. 2014 Apr;43(4):301-9. (PMID: 24630305)
Actas Urol Esp. 2014 Jul-Aug;38(6):391-6. (PMID: 24775812)
Clin Infect Dis. 2015 Apr 1;60(7):979-87. (PMID: 25516194)
J Antimicrob Chemother. 2015 Jul;70(7):2068-73. (PMID: 25802286)
BJU Int. 2008 May;101(10):1201-2. (PMID: 18336605)
J Urol. 2008 Apr;179(4):1379-90. (PMID: 18280509)
Urology. 2009 Jul;74(1):119-23. (PMID: 19464043)
معلومات مُعتمدة: R01 AI106007 United States AI NIAID NIH HHS; R01AI106007 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (Anti-Bacterial Agents)
0 (Fluoroquinolones)
8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination)
تواريخ الأحداث: Date Created: 20150825 Date Completed: 20160510 Latest Revision: 20181113
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC4698053
DOI: 10.1016/j.urology.2015.07.008
PMID: 26299464
قاعدة البيانات: MEDLINE
الوصف
تدمد:1527-9995
DOI:10.1016/j.urology.2015.07.008